Evidence mapPaperPMID 35486388Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Deterioration of Glycemic Control in Youth-Onset Type 2 Diabetes: What Are the Early and Late Predictors?

Philip Zeitler, Laure El Ghormli, Silva Arslanian, Sonia Caprio, Elvira Isganaitis, Megan K Kelsey, Ruth S Weinstock, Neil H White, Kimberly Drews

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Diabetic Ketoacidosis and Long-term Insulin Requirements in Youths with Newly Diagnosed Type 2 Diabetes During the SARS-CoV-2 Pandemic.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Philip ZeitlerUniversity of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-5756-7858
Laure El GhormliThe Biostatistics Center, George Washington University, Rockville, MD 20852,USA.ORCID 0000-0003-4223-8407
Silva ArslanianUniversity of Pittsburgh, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15213,USA.ORCID 0000-0002-1528-9324
Sonia CaprioYale University, New Haven, CT 06520,USA.ORCID 0000-0002-7523-5053
Elvira IsganaitisJoslin Diabetes Center, Boston, MA 02215, USA.ORCID 0000-0003-3477-0305
Megan K KelseyUniversity of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-0755-1951
Ruth S WeinstockState University of New York Upstate Medical University, Syracuse, NY 13210, USA.ORCID 0000-0001-5859-5666
Neil H WhiteWashington University in St. Louis School of Medicine, St. Louis, MO 63110,USA.
Kimberly DrewsThe Biostatistics Center, George Washington University, Rockville, MD 20852,USA.
George Washington University · USUniversity of Colorado Anschutz Medical Campus · USJoslin Diabetes Center · USSUNY Upstate Medical University · USUniversity of Pittsburgh · USWashington University in St. Louis · USYale University · US

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1985 to 2005
$43.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
ZIPRASIDONE IN TOURETTES SYNDROME, OBSESSIVE COMPULSIVE &PERVASIVE DEV. DISORDERM01RR000125 · YALE UNIVERSITY · 1985 to 2005
$20.7M
XANAX PET SCAN/IV LACTATE PANIC STUDYM01RR000036 · WASHINGTON UNIVERSITY · 1985 to 2005
$20.4M
ZORVIRAX ORAL SUSPENSION FOR SEVERE CHILDHOOD HERPES VIRUS INFECTIONSM01RR000069 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$15.4M
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1M
Yale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$10.1M
Yale Clinical and Translational Science AwardUL1TR001863 · YALE UNIVERSITY · 2025 to 2025
$9.9M
Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · UNIVERSITY OF COLORADO DENVER · 1995 to 2025
$7.7M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002535NCATS NIH HHS UL1 TR002541NCATS NIH HHS UL1 TR002548NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000043NCRR NIH HHS M01 RR000069NCRR NIH HHS M01 RR000084NCRR NIH HHS M01 RR000125NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR014467NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK116073NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254
6 · The paper itself

Abstract

objectiveWe examined predictors of early and late loss of glycemic control in individuals with youth-onset type 2 diabetes, as well as predictors of short-term deterioration in youth from the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.

methodsDemographic, physical, and biochemical measures at baseline and 48 months, and change over time, were examined in 584 participants separated into those with loss of glycemic control (sustained HbA1c ≥ 8%) before 48 months or at 48 months or later, and those who remained in control until the end of the study (median 6.8 years). Univariate and multivariate models, and receiver operating characteristic curve analyses were performed.

resultsApproximately 45% of youth remained in control at 48 months; of these, 30% subsequently lost glycemic control prior to the end of follow-up. Predictors of early loss of glycemic control included baseline HbA1c, C-peptide index, oral disposition index, proinsulin, and proinsulin to insulin ratio. Predictors of late loss included baseline measures of insulin secretion and change in HbA1c and insulin processing at 48 months. A baseline HbA1c cutoff of ≥ 6.2% was optimally predictive of loss of glycemic control at any time, while an absolute rise in HbA1c > 0.5% related to loss of glycemic control within 3 to 6 months.

conclusionThis analysis demonstrates that youth with type 2 diabetes at risk for loss of glycemic control, including impending rapid deterioration, can be identified using available clinical measures, allowing for closer monitoring of at-risk youth, and facilitating the design of research on better therapeutic options.

Indexed as

Diabetes Mellitus, Type 2Glycemic ControlTreatment FailureAdolescentAge of OnsetBlood GlucoseGlycated HemoglobinHumansProinsulinBlood GlucoseGlycated HemoglobinProinsulinglycemic controlrisk factorstype 2 diabetesyouth

Identifiers

PMID35486388
PMCPMC9653021
OpenAlexW4225127173

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.